[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-381833-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-381833-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-mechanisms-of-tumor-progression-and-new-therapeutic-strategies-for-urological-cancers","Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers","","Editorial overview of molecular drivers behind tumor progression and therapy resistance in urological cancers, emphasizing bladder, prostate, renal, upper urinary tract, and germ cell malignancies. Highlights rising incidence over recent decades and the clinical need for mechanistic insight to improve diagnostics and therapeutic selection. Describes contributions within a Special Issue, covering predictive biomarkers and emerging strategies including immunotherapy and targeted therapy, with examples drawn from renal cell carcinoma and metastatic disease research.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-mechanisms-of-tumor-progression-and-new-therapeutic-strategies-for-urological-cancers/381833/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-mechanisms-of-tumor-progression-and-new-therapeutic-strategies-for-urological-cancers/381833.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the focus of this editorial?","Question",{"text":63,"@type":64},"It focuses on molecular mechanisms driving tumor progression and therapy resistance in urological cancers and on new therapeutic strategies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why does the editorial emphasize the molecular study of urological cancers?",{"text":68,"@type":64},"Because improved understanding of molecular mechanisms and therapy resistance is needed to develop novel treatments, predict drug response, and support precision medicine.",{"name":70,"@type":61,"acceptedAnswer":71},"Which treatment approaches are highlighted for urological cancers?",{"text":72,"@type":64},"The editorial highlights immunotherapy and targeted therapies, including tyrosine kinase inhibitors and immune checkpoint inhibitors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},381833,1790638909,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},4398046744996,"Editorial  \nMolecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers  \nVicenç Ruiz de Porras 1,2,3, * and Albert Font 1,2,4, *  \nCitation: Ruiz de Porras, V.; Font, A. Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers. Int.  \nJ. Mol. Sci. 2023, 24, 15795. [https://](https://)[ ](https://)[doi.org/10.3390/ijms242115795](doi.org/10.3390/ijms242115795)  \nReceived: 23 October 2023  \nAccepted: 26 October 2023  \nPublished: 31 October 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 CARE Program, Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain  \n2 Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B􀀁ARGO), 08916 Badalona, Spain  \n3 Grup de Recerca en Toxicologia (GRET), Unitat de Toxicologia, Departament de Farmacologia, Toxicologia i Qu½mica Terap±utica, Facultat de Farm cia i Ci±ncies de l'Alimentaciâ, Universitat de Barcelona, Avda. Joan XXIII s/n, 08028 Barcelona, Spain  \n4 Medical Oncology Department, Catalan Institute of Oncology, 08916 Badalona, Spain  \n* [Correspondence: vruiz@igtp.cat](Correspondence: vruiz@igtp.cat) (V.R.d.P.); [afont@iconcologia.net](afont@iconcologia.net) (A.F.); Tel.: +34-935-54-31-69 (V.R.d.P.);+34-934-97-89-25 (A.F.)  \nUrological cancer encompasses a diverse range of tumors, including bladder, prostate, renal, upper urinary tract, and germ cell tumors. Over the past four decades, the incidence of urological cancers has increased significantly, making them a major global health concern. Strikingly, each of these urological cancers is consistently among the top ten most prevalent malignancies, contributing significantly to the overall cancer burden. This surge in incidence is particularly pronounced in men, where urological tumors collectively account for up to 33% of all reported malignancies [1] . This epidemiological reality underscores the urgent need to increase our understanding of these cancers, each of which is characterized by distinct pathogenetic mechanisms and requires varied diagnostic and therapeutic approaches. Despite considerable advances in the treatment options for urological tumors, including the integration of novel approaches such as immunotherapy and targeted therapies [2], an improved understanding of the molecular mechanisms of tumor progression and therapy resistance will help us develop novel treatment strategies and predict drug response, thus aiding our progress toward precision medicine. In this Special Issue, we have compiled a series of original research articles and a comprehensive review that explore various aspects of our emerging knowledge of molecular biology, novel mechanisms of therapy resistance, predictive biomarkers, and cutting-edge therapeutic strategies in the field of urological cancers.  \nIn the quest for improved treatments for urological tumors, research on renal cell carcinoma (RCC) has taken a prominent role. RCC is the most prevalent kidney cancer in adults, with clear-cell RCC (ccRCC) being the most commonly diagnosed [1] . Recent studies have demonstrated that several genetic polymorphisms play a pivotal role in the prognosis of RCC and can significantly influence patient outcomes following treatment [3] . Andrzejczak and colleagues have investigated the role of polymorphisms of mucin-domaincontaining-3 (TIM-3) and its ligand, galectin-9 (LGALS9), in terms of susceptibility to ccRCCand in terms of overall patient survival (OS) . Their results showed an association between some single-nucleotide polymorphisms (SNPs) and clinical features and between the TIM-3 genetic variant rs1036199 and a shorter OS. Their findi","cbCaidOHW64AQQk4","https://ap.wps.com/l/cbCaidOHW64AQQk4","pdf",224589,"English","# Editorial\n## Epidemiological burden and clinical need\n## Precision medicine and emerging strategies\n## Focus areas in renal cell carcinoma and metastatic RCC","[{\"question\":\"What is the focus of this editorial?\",\"answer\":\"It focuses on molecular mechanisms driving tumor progression and therapy resistance in urological cancers and on new therapeutic strategies.\"},{\"question\":\"Why does the editorial emphasize the molecular study of urological cancers?\",\"answer\":\"Because improved understanding of molecular mechanisms and therapy resistance is needed to develop novel treatments, predict drug response, and support precision medicine.\"},{\"question\":\"Which treatment approaches are highlighted for urological cancers?\",\"answer\":\"The editorial highlights immunotherapy and targeted therapies, including tyrosine kinase inhibitors and immune checkpoint inhibitors.\"}]","Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers | PDF",1790247395,13]